You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY22 is not expected to be complete until September, 2023.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

Displaying 196171 - 196180 of 201435 results
  1. Interstitial Chemophototherapy with Light-Activated Nanoparticulate Doxorubicin

    SBC: POP Biotechnologies Inc.            Topic: NCI

    Summary Our goal is to commercialize interstitial chemo-phototherapy (I-CPT) as a new therapeutic option for locally advanced liver cancers. Doxorubicin (Dox) can be actively loaded into long circulating, serum-stable, porphyrin- phospholipid (PoP) liposomes and be released with 665-nm laser light (PhotoDox). This approach leads to vastly enhanced drug accumulation in irradiated tissues, resulting ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  2. Development of a novel accurate therapy for multiple sclerosis

    SBC: Autoimmunity Biologic Solutions, Inc.            Topic: NIAID

    PROJECT SUMMARYMultiple Sclerosis (MS) is the most common neurological disease of early adulthood and is mediated by autoimmune mechanisms that lead to demyelination and neuronal damage in the central nervous system, resulting in progressive neurological dysfunction. Up to date, there is no cure for this devastating disease and current available treatments focus on preventing future immunological ...

    STTR Phase II 2022 Department of Health and Human ServicesNational Institutes of Health
  3. Simple Method for Screening of HIV Drug Resistance in Resource-Limited Settings

    SBC: Discidium Biosciences, LLC            Topic: NIAID

    Abstract Drug resistance to antiretroviral therapy for HIV infection is a serious clinical problem without cost-effective solutions in low and middle-income countries (LMICs) where standard genotypic resistance assays are unaffordable. Discidiumandapos;s goal is to develop a single tube assay that uses lyophilized reactants, standard PCR and in-tube readout, that can be used as a screening resista ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  4. Reduction of Pigmentation Dependent Errors using Spectroscopic Pulse Oximetery

    SBC: Aimloxy LLC            Topic: NIGMS

    PROJECT SUMMARY/ ABSTRACT Pulse oximetry is a powerful clinical tool for clinical evaluation of patients with cardiopulmonary compromise, however, multiple clinical studies have indicated pulse oximetry suffers from overestimation errors in darkly pigmented individuals, which is a critical mistake in screening for a cardiopulmonary disease, including COVID- 19, and could contribute to reports of o ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  5. Novel platform for optimizing AAV transgene expression to improve efficacy of ocular gene therapies

    SBC: Epigenos Bioscience, Inc.            Topic: 100

    Abstract Gene therapy applications based on adeno-associated virus (AAV) have demonstrated promise in clinical applications for the treatment of diverse genetic diseases highlighted by the recent FDA approval of AAV vector formulations as new drugs for ocular and neurological diseases. In these instances, along with all applications of clinical AAV gene therapy to date, constitutive transcription ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  6. Preclinical testing of a 3D printed external scaffold device to prevent vein graft failure after coronary bypass graft surgery

    SBC: BIOGRAFT, INC.            Topic: NHLBI

    Saphenous vein graft (SVG) failure following coronary artery bypass grafting (CABG) is a critical clinical problem, with recent studies revealing that as many as 25% of vein grafts develop stenosis within 12-18 months after surgery, and up to 50% of grafts occlude within 5-10 years. CABG surgery is the gold standard treatment for patients with severe multi-vessel disease, with over 370,000 procedu ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  7. Assessment of mobile application-delivered lighting interventions for reducing circadian disruption in shift workers

    SBC: ARCASCOPE INC            Topic: NHLBI

    PROJECT SUMMARY Shift workers experience profound circadian disruption, which can have deleterious long term effects on their health and quality of life. Mood, fatigue, and performance can be improved in shift workers by moving the timing of their peak circadian drive to sleep outside the hours they are expected to work. This can be achieved with a targeted lighting intervention, as light is the p ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  8. Point-of-care microdevices for simultaneous detection of multiple pertussis-like respiratory diseases from Bordetella species

    SBC: MICROBIOCHIP DIAGNOSTICS LLC            Topic: NIAID

    ABSTRACT Pertussis, also known as whooping cough, caused by B. pertussis and B. parapertussis, is the only vaccine-preventable infection that remains endemic in the U.S. Since pertussis vaccine- induced immunity is not permanent, the immunized host is vulnerable to re-infection later in life. Worldwide, there are an estimated 24.1 million cases of pertussis, and about 160,700 deaths per year from ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  9. Liquid Immunogenic Fiducial Eluter (LIFE) for Cervical Cancer Treatment

    SBC: NANOCAN THERAPEUTICS CORPORATION            Topic: 102

    Project SummaryCurrent treatment options for advanced cervical cancer are limited, with a 5-year overall survival rate of 17%. In the USA, pervasive disparities remain in access to treatment and mortality, disproportionately affecting African American and Latino populations. Innovative therapeutic approaches for metastatic disease that can increase access to care and reduce disparities are greatly ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
  10. Development and Evaluation of Rosette Array Technology for HumanNeurodevelopmental Toxicity Screening

    SBC: Neurosetta LLC            Topic: 113

    Project Summary Pre-clinical and pre-field toxicology testing of new drugs and chemicals does not routinely include direct assessment of human developmental neurotoxicity (DNT). Current standards for DNT testing require use of animal models with limited throughput and significant differences from human central nervous system (CNS) development. As such, many chemical products have required post-app ...

    STTR Phase I 2022 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government